Prognostic Value of Biomarkers in RCC

Video

Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.

Recent Videos
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Related Content
Safety data from the phase 2 LITESPARK-003 trial evaluating belzutifan/cabozantinib in renal cell carcinoma show no treatment-related deaths.

Belzutifan/Cabozantinib Elicits Promising Activity in Clear Cell RCC

Roman Fabbricatore
January 10th 2025
Article

Safety data from the phase 2 LITESPARK-003 trial evaluating belzutifan/cabozantinib in renal cell carcinoma show no treatment-related deaths.

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.

Highlighting Advocacy Impacts on Funding for Kidney Cancer Research

Elizabeth P. Henske, MD;Jason B. Muhitch, PhD
December 16th 2024
Podcast

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.

Discussing Immunotherapy Options in Advanced Non–Clear Cell RCC

Discussing Immunotherapy Options in Advanced Non–Clear Cell RCC

ONCOLOGY Staff
December 26th 2024
Article

The program was brought together to discuss immunotherapy options for non–clear cell RCC in light of emerging clinical trial data and NCCN guidelines.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Addressing Gaps in Education for Non–Clear Cell RCC

Addressing Gaps in Education for Non–Clear Cell RCC

ONCOLOGY Staff
November 19th 2024
Article

A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors

José Luis Rodríguez-Olivares, MD;Héctor Raúl González-Sánchez, MD;Evelyn Lilian Beas-Lozano, MD;Jazmin Arteaga-Vázquez, MD;Elaine T. Lam, MD;María T. Bourlon, MD, MSc, FASCO
October 22nd 2024
Article

A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.